McKesson (NYSE:MCK) Releases FY 2027 Earnings Guidance

McKesson (NYSE:MCK) updated its FY 2027 earnings guidance on Wednesday. The company provided EPS guidance of 44.200-45.000 for the period, compared to the consensus earnings per share estimate of 44.270. The company issued revenue guidance of $423.6 billion-$439.7 billion, compared to the consensus revenue estimate of $431.9 billion.

Wall Street Analyst Weigh In

Several research firms have weighed in on MCK. Barclays dropped their target price on McKesson from $1,050.00 to $925.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Wall Street Zen lowered shares of McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. William Blair initiated coverage on shares of McKesson in a report on Tuesday, April 28th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. cut their target price on shares of McKesson from $1,107.00 to $1,015.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Finally, Wells Fargo & Company decreased their price target on shares of McKesson from $925.00 to $812.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $968.93.

McKesson Stock Performance

Shares of NYSE:MCK traded up $0.34 during trading hours on Friday, reaching $871.72. The stock had a trading volume of 1,491,318 shares, compared to its average volume of 955,920. The stock has a market capitalization of $102.06 billion, a price-to-earnings ratio of 23.33, a P/E/G ratio of 1.44 and a beta of 0.30. The firm’s 50 day moving average is $798.08 and its 200-day moving average is $840.76. McKesson has a 1 year low of $637.00 and a 1 year high of $999.00.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.56 by $0.37. McKesson had a negative return on equity of 371.86% and a net margin of 1.12%.The business had revenue of $105.38 billion during the quarter, compared to analysts’ expectations of $103.88 billion. During the same period in the prior year, the firm posted $8.26 EPS. The business’s quarterly revenue was up 7.7% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Analysts forecast that McKesson will post 44.28 EPS for the current year.

McKesson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. This is an increase from McKesson’s previous quarterly dividend of $0.82. The ex-dividend date is Tuesday, September 1st. McKesson’s payout ratio is presently 8.53%.

Insider Transactions at McKesson

In related news, CAO Napoleon B. Rutledge, Jr. sold 133 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $764.00, for a total value of $101,612.00. Following the completion of the sale, the chief accounting officer owned 632 shares in the company, valued at $482,848. This represents a 17.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Brian S. Tyler sold 8,463 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $793.56, for a total transaction of $6,715,898.28. Following the sale, the chief executive officer owned 5,919 shares of the company’s stock, valued at approximately $4,697,081.64. This represents a 58.84% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 28,748 shares of company stock valued at $22,262,035 over the last quarter. Company insiders own 0.06% of the company’s stock.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson reported fiscal Q1 adjusted earnings of $9.93 per share, above the roughly $9.44–$9.56 analyst estimates and up from $8.26 a year earlier. Revenue rose 7.7% to $105.38 billion, also exceeding expectations. McKesson Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: The company raised fiscal 2027 adjusted EPS guidance to $44.20–$45.00, broadly above the prior consensus forecast, supported by a 19% increase in pharmaceutical profit, continued specialty-drug demand and oncology growth. MCK Q1 Earnings Call Centers on Pharma-Led Guidance Raise
• Positive Sentiment: McKesson outlined plans for approximately $5 billion in share repurchases and announced a 15% dividend increase, providing additional support for per-share earnings and shareholder returns. McKesson Fiscal 2027 EPS and Share Repurchase Plans
• Neutral Sentiment: McKesson is rebranding its Medical-Surgical Solutions business as Wellverse ahead of a planned separation or IPO. The move could eventually highlight the unit’s value, but the transaction also introduces execution and timing uncertainty. McKesson Debuts Wellverse Name

Institutional Investors Weigh In On McKesson

Hedge funds have recently modified their holdings of the stock. Sunbelt Securities Inc. raised its stake in shares of McKesson by 10.3% during the 4th quarter. Sunbelt Securities Inc. now owns 545 shares of the company’s stock worth $447,000 after buying an additional 51 shares in the last quarter. Compound Planning Inc. grew its holdings in shares of McKesson by 92.9% in the 4th quarter. Compound Planning Inc. now owns 2,598 shares of the company’s stock worth $2,131,000 after acquiring an additional 1,251 shares during the period. Invesco Ltd. raised its holdings in McKesson by 9.5% during the fourth quarter. Invesco Ltd. now owns 1,052,739 shares of the company’s stock worth $863,551,000 after purchasing an additional 90,982 shares during the last quarter. Birchwood Financial Partners Inc. purchased a new position in shares of McKesson in the fourth quarter valued at $33,000. Finally, Mercer Global Advisors Inc. ADV raised its stake in shares of McKesson by 7.0% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 29,913 shares of the company’s stock worth $23,028,000 after buying an additional 1,956 shares during the last quarter. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.